Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prothymosin alpha pseudogene 4 (PTMAP4) is a processed, non-coding pseudogene belonging to the human prothymosin alpha gene family[1][2][4]. Pseudogenes like PTMAP4 share sequence similarity with the functional prothymosin alpha gene (PTMA), but do not encode active proteins: they lack regulatory elements or carry sequence changes that prevent proper expression[2]. Most studies (and genomic databases such as HGNC and Ensembl) identify PTMAP4 on human chromosome 12 and confirm it is not transcriptionally active in human tissues[1][2][4]. There is one functional prothymosin alpha gene in humans—PTMA—whose protein product is involved in cell proliferation, apoptosis, and immune responses[5][6]. PTMAP4, however, does not contribute directly to these functions, and there is no current evidence that it has a biological or disease-related role[2][3][4]. Because it is a pseudogene, it is not considered a therapeutic target. If you meant the functional **prothymosin alpha** (PTMA) gene product, please clarify, as information on that functional protein—including its biological and disease relevance—differs significantly[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prothymosin alpha pseudogene 4 (PTMAP4).